• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.

作者信息

Escobar Miguel, Dunn Amy, Quon Doris, Trzaskoma Ben, Lee Lucy, Ko Richard H, Carpenter Shannon L

机构信息

University of Texas Health Science Center, Houston, Texas, USA.

Nationwide Children's Hospital, Columbus, Ohio, USA.

出版信息

Haemophilia. 2022 Jul;28(4):e105-e108. doi: 10.1111/hae.14574. Epub 2022 May 5.

DOI:10.1111/hae.14574
PMID:35510949
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9544354/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46a4/9544354/c4cdf4abe248/HAE-28-e105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46a4/9544354/c4cdf4abe248/HAE-28-e105-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/46a4/9544354/c4cdf4abe248/HAE-28-e105-g001.jpg

相似文献

1
A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.一项关于emicizumab预防在接受小手术的有或无FVIII抑制剂的A型血友病患者中的IV期、多中心、开放标签研究。
Haemophilia. 2022 Jul;28(4):e105-e108. doi: 10.1111/hae.14574. Epub 2022 May 5.
2
Emicizumab-kxwh: First Global Approval.依美珠单抗-kxwh：全球首次获批。
Drugs. 2018 Feb;78(2):269-274. doi: 10.1007/s40265-018-0861-2.
3
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.每4周给予艾美赛珠单抗预防治疗A型血友病患者的疗效、安全性及药代动力学（HAVEN 4）：一项多中心、开放标签、非随机3期研究
Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.
4
A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.一种改良的凝血酶生成试验，用于评估在emicizumab（一种针对IXa/X因子的双特异性抗体）存在下的血浆凝血潜力。
Int J Hematol. 2020 Nov;112(5):621-630. doi: 10.1007/s12185-020-02959-x. Epub 2020 Aug 3.
5
Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.依库珠单抗对人工添加因子 VIII 的血浆标本和有抑制物的血友病 A 患者样本的 APTT、一步法及显色法检测因子 VIII 的影响。
Haemophilia. 2020 May;26(3):536-542. doi: 10.1111/hae.13990. Epub 2020 Apr 6.
6
Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.转换为艾美赛珠单抗：一项针对患有抑制剂的甲型血友病患者的前瞻性监测研究。
Haemophilia. 2023 Jan;29(1):348-351. doi: 10.1111/hae.14685. Epub 2022 Oct 31.
7
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.人源化双特异性抗体在血友病 A 中模拟因子 VIII 的功能。
N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769.
8
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis.接受emicizumab预防治疗的血友病 A 伴抑制物患儿的免疫耐受诱导。
Haemophilia. 2019 Sep;25(5):789-796. doi: 10.1111/hae.13819. Epub 2019 Aug 2.
9
Emicizumab in people with moderate or mild haemophilia A (HAVEN 6): a multicentre, open-label, single-arm, phase 3 study.依库珠单抗治疗中重度及轻度甲型血友病患者（HAVEN 6）：一项多中心、开放标签、单臂、3 期研究。
Lancet Haematol. 2023 Mar;10(3):e168-e177. doi: 10.1016/S2352-3026(22)00377-5. Epub 2023 Jan 27.
10
Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.接受emicizumab预防出血事件的血友病 A 患者延迟抑制剂开发的经济影响模型。
J Med Econ. 2019 Dec;22(12):1328-1337. doi: 10.1080/13696998.2019.1669614. Epub 2019 Oct 7.

引用本文的文献

1
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors.来自STASEY研究的手术经验：emicizumab预防A型血友病伴凝血因子VIII抑制剂患者的情况
TH Open. 2024 Jan 12;8(1):e42-e54. doi: 10.1055/s-0043-1777766. eCollection 2024 Jan.
2
Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center.接受艾美赛珠单抗预防治疗的甲型血友病患者的手术管理：来自一个国家血友病治疗中心的数据。
Res Pract Thromb Haemost. 2023 Aug 23;7(6):102178. doi: 10.1016/j.rpth.2023.102178. eCollection 2023 Aug.
3

本文引用的文献

1
Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.HAVEN 1-4 研究中依库珠单抗预防伴或不伴 FVIII 抑制剂的血友病 A 的长期疗效。
Blood. 2021 Apr 22;137(16):2231-2242. doi: 10.1182/blood.2020009217.
2
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US.接受emicizumab预防治疗的 A 型血友病患者手术管理：来自美国大型综合治疗中心的真实世界经验。
Haemophilia. 2021 Jan;27(1):90-99. doi: 10.1111/hae.14212. Epub 2020 Nov 27.
3
Antithrombotic Treatment in Patients With Hemophilia: an EHA-ISTH-EAHAD-ESO Clinical Practice Guidance.
血友病患者的抗血栓治疗：欧洲血液学协会-国际血栓与止血学会-欧洲遗传性血管性水肿协会-欧洲血友病治疗协会临床实践指南
Hemasphere. 2023 Jun 5;7(6):e900. doi: 10.1097/HS9.0000000000000900. eCollection 2023 Jun.
4
Management of children with hemophilia A on emicizumab who need surgery.接受依美珠单抗治疗的需要手术的甲型血友病患儿的管理。
Front Pediatr. 2023 Apr 4;11:1155853. doi: 10.3389/fped.2023.1155853. eCollection 2023.
5
Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies.接受艾美赛珠单抗预防治疗的 A 型血友病患者的手术结局：来自 HAVEN 1-4 研究的经验。
Blood Adv. 2022 Dec 27;6(24):6140-6150. doi: 10.1182/bloodadvances.2022007458.
WFH Guidelines for the Management of Hemophilia, 3rd edition.
《血友病管理的居家指南》第三版
Haemophilia. 2020 Aug;26 Suppl 6:1-158. doi: 10.1111/hae.14046. Epub 2020 Aug 3.
4
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures.艾美赛珠单抗在血友病 A 患者中的真实世界应用：出血结局和手术操作。
Haemophilia. 2020 Jul;26(4):631-636. doi: 10.1111/hae.14005. Epub 2020 Apr 20.
5
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors.依库珠单抗预防治疗有和无抑制剂的血友病 A 患者。
Haemophilia. 2020 Jan;26(1):41-46. doi: 10.1111/hae.13877. Epub 2019 Nov 20.
6
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.一项emicizumab 预防治疗伴抑制物的血友病 A 患儿的多中心、开放性 3 期研究。
Blood. 2019 Dec 12;134(24):2127-2138. doi: 10.1182/blood.2019001869.
7
Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.双特异性抗体emicizumab对因子IX/IXa和X/Xa的VIIIa模拟辅因子活性取决于其桥接抗原的能力。
Thromb Haemost. 2017 Jun 28;117(7):1348-1357. doi: 10.1160/TH17-01-0030. Epub 2017 Apr 28.
8
Definitions in hemophilia: communication from the SSC of the ISTH.血友病的定义：来自国际血栓与止血学会（ISTH）科学标准化委员会（SSC）的交流文件
J Thromb Haemost. 2014 Nov;12(11):1935-9. doi: 10.1111/jth.12672. Epub 2014 Sep 3.